Merus - נכסים נקיים למניה בודדת MRUS

Merus N.V. (MRUS) specializes in therapies for female oncological diseases, leveraging its authority in creating unique antibodies. The linear price action on this chart confirms the business's resilience, as drug development is not subject to macroeconomic shocks or seasonality. Strict FDA regulations and costly R&D ensure a high barrier to entry, and the current metric stands at 10.22, highlighting the protection of intellectual property.

Investors utilize the margin of safety to assess the real value of assets relative to the market price. For Merus N.V., which focuses on developing anti-cancer antibodies, this reserve is critical when funding laboratory research. The financial metric of book value per share, equal to 10.22, is calculated as the ratio of equity to the number of shares. This metric strips fundamental value of price volatility. A high value confirms the resilience of the biotech startup.